---
layout: default
title: Alpha -Tocopherol Acetate Dl- Beta -Carotene 5-Met
parent: 僅模型預測 (L5)
nav_order: 228
evidence_level: L5
indication_count: 0
---

# Alpha -Tocopherol Acetate Dl- Beta -Carotene 5-Met
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multivitamin-Mineral Complex: No Predicted New Indication Available

## One-Sentence Summary

This candidate is a comprehensive multivitamin-mineral combination containing 18 active ingredients, including fat-soluble vitamins (Vitamin D3, E, beta-carotene), water-soluble vitamins (B1, B2, B3, B6, B12, C, biotin, folic acid, 5-MTHF), and trace minerals (iron, zinc, copper, magnesium, calcium, potassium iodide).
The TxGNN model did not generate any predicted new indications for this multi-component combination.
**No clinical trial or literature evidence could be retrieved**, and this candidate is currently **not marketed in Taiwan**, making a full repurposing evaluation infeasible at this stage.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Unknown (no regulatory filings on record) |
| Predicted New Indication | N/A — no TxGNN predictions generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | Not Evaluable |
| Taiwan Market Status | ✗ Not Marketed |
| Number of Licenses | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Not Available?

The query target is not a single molecular entity but an 18-component nutritional formula combining vitamins, provitamins, and inorganic mineral salts. The TxGNN knowledge graph is designed to operate on individual drug nodes (DrugBank IDs); a compound mixture without a unified DrugBank entry cannot be mapped to the knowledge graph, which explains why `predicted_indications` returned an empty array.

Furthermore, while individual components such as folic acid, cholecalciferol, and ascorbic acid each have well-characterised mechanistic roles in haematopoiesis, bone metabolism, and antioxidant defence, the combination as a single unit does not correspond to any disease-drug relationship node in the TxGNN graph. Generating a repurposing prediction would require either splitting the combination into individual INN queries or defining a virtual composite node — neither of which was performed in this pipeline run.

---

## Clinical Trial Evidence

Currently no related clinical trials registered for this combination as a unified candidate.

---

## Literature Evidence

Currently no related literature available for this combination as a unified TxGNN candidate.

---

## Taiwan Market Information

This combination has **0 regulatory licenses** on record in the Taiwan FDA (TFDA) database. No approved product data is available to display.

---

## Safety Considerations

Please refer to the package insert for safety information.

No drug-drug interaction data was returned (DDI query status: not found). No key warnings or contraindications data is available in the current Evidence Pack.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN pipeline cannot process an 18-component mixture as a single drug entity because no unified DrugBank ID exists for this combination, resulting in zero predictions and zero retrievable evidence. A repurposing evaluation is not feasible without resolving the data structure issues first.

**To proceed, the following is needed:**

- **Decompose the query**: Re-run TxGNN predictions for each of the 18 individual INNs separately (e.g., folic acid → DB00158, cholecalciferol → DB00169, ascorbic acid → DB00126) and aggregate results
- **Assign DrugBank IDs**: Map each component to its individual DrugBank entry so the knowledge graph can be traversed
- **Define the clinical question**: Clarify whether the goal is repurposing the full combination or evaluating individual micronutrients for specific indications
- **Regulatory verification**: Confirm whether any single-component or similar combination products are filed under TFDA or US FDA (NDA/OTC monograph)
- **MOA documentation**: Retrieve mechanism-of-action data for each component from DrugBank to support mechanistic plausibility analysis
- **Safety data**: Download individual component package inserts to populate key warnings and contraindication fields
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

